Alzheimer’s Disease (AD) may be amenable to PACAP-based therapies, as PACAP is involved with learning and memory formation [71,80] and exerts neuroprotection [95]. This evidence concerns the gene ADCYAP1 and early-onset autosomal dominant Alzheimer disease.